Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. operates as a healthcare services fertility company focused on assisted reproductive technology care through the establishment, acquisition and operation of fertility clinics and related technologies. Company news commonly covers clinic expansion, acquired fertility practices, network relationships, laboratory capabilities and the use of the INVOcell medical device for intravaginal culture procedures.
Recurring updates also include intellectual-property developments for INVOcell, operational changes at U.S. fertility clinics, capital-structure actions such as reverse stock splits, shareholder communications, securities-listing compliance matters and financial-reporting status. Recent company materials also identify Family Beginnings and Wisconsin Fertility Institute as part of the clinic platform.
INVO Fertility (Nasdaq: IVF) received a Nasdaq notice on April 23, 2026 for late filing of its Form 10-K for the year ended December 31, 2025, which was due April 15, 2026.
The notice does not affect the company's current Nasdaq listing or trading. The delay stems from additional time needed to review complex accounting matters, including the tax provision, warrant accounting, and variable interest entity accounting. The company has 60 calendar days to submit a compliance plan; Nasdaq may grant up to 180 days from the due date if the plan is accepted.
INVO Fertility (NASDAQ: IVF) will effect a 1-for-5 reverse stock split of its issued, outstanding and authorized common stock at 12:01 a.m. ET on March 27, 2026.
Post-split trading on The Nasdaq Capital Market will continue under the symbol IVF, the CUSIP will be 44984F880, and issued shares will total approximately 1,615,419. Authorized shares will be adjusted to 50,000,000. Fractional shares for registered holders will be rounded up; beneficial holders in street name will receive cash in lieu per broker procedures.
INVO Fertility (Nasdaq: IVF) announced on March 5, 2026 that it has adopted time-lapse incubation technology at its Wisconsin clinic to enhance laboratory care and patient experience. The company says the FDA-cleared system enables continuous embryo monitoring, supports embryo selection, and provides patients video records of development.
This move aligns with INVO’s stated strategy to invest in modern reproductive technologies and strengthen clinical and laboratory capabilities across its clinic network.
INVO Fertility (Nasdaq: IVF) announced that its Wisconsin Fertility Institute clinic joined the Progyny network effective March 3, 2026. Progyny covers an estimated 7.2 million lives through over 600 employers, giving WFI in-network access to employer-sponsored patients and expanded payor mix.
Eligible patients gain in-network access to diagnostic testing, IVF, fertility preservation and advanced treatments. The company says the move supports scaling clinic reach, deepening payor relationships, and driving long-term growth across its clinic platform.
INVO Fertility (Nasdaq: IVF) closed its acquisition of Family Beginnings, a Midwest fertility clinic, on Feb 19, 2026 for a $760,000 combined purchase price paid in cash and preferred stock. Family Beginnings reported ~$1.0M revenue and ~$0.2M net income for the nine months ended Sept 30, 2025, representing about 18% of INVO's clinic revenue for that period.
The clinic’s medical leadership and care teams remain in place under a multi-year agreement with James Donahue, M.D., and INVO intends to provide operational support and technology investment to expand patient access.
INVO Fertility (Nasdaq: IVF) announced issuance of U.S. Patent No. 12,544,204 B2 effective February 10, 2026, covering a modified INVOcell device design. The patent extends intellectual property protection for the INVOcell intravaginal culture system through 2040. The device has prior FDA clearances in 2015 and a 2023 labeling update.
INVO Fertility (Nasdaq: IVF) CEO Steve Shum issued a shareholder letter outlining operational progress, a strengthened balance sheet, and a dual growth strategy of organic initiatives plus clinic acquisitions. The company operates three profitable clinics, is nearing a fourth-clinic acquisition in Indianapolis, and reports a combined pro forma annualized clinic revenue run rate of approximately $9 million.
Management cites a January 2026 warrant inducement priced at $1.59, simplified capital structure, and expectations for strong growth in 2026 driven by clinic expansion and organic volume gains.
INVO Fertility (NASDAQ: IVF) entered a warrant inducement agreement to lower the exercise price of December 2025 warrants to $1.59 and has an investor agreeing to immediately exercise warrants to buy 4,733,728 shares, generating approximately $7.5 million gross proceeds before fees.
The company will issue 9,467,456 new unregistered warrants at $1.59 per share, subject to shareholder approval, and expects to close the exercise on or about January 30, 2026, subject to customary conditions.
INVO Fertility (Nasdaq: IVF) will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026. The live webcast begins at 3:00 p.m. ET and will be available at the conference page https://lythampartners.com/hc2026/ivf. A replay will be accessible at the same link after the event. The company focuses on establishing, acquiring, and operating fertility clinics and related technologies.
INVO Fertility (Nasdaq: IVF) announced an executive realignment effective Dec. 30, 2025 to support its clinic-acquisition growth strategy. Terah Krigsvold, controller since Dec. 2020, is appointed chief financial officer, replacing Andrea Goren. Andrea Goren, CFO since July 2021, becomes chief business officer and CEO of INVO Centers LLC, the company's wholly owned clinic subsidiary, to lead acquisitions and new clinic launches. Management says the move preserves finance continuity while shifting Andrea to focus on growth and transactions. The release notes Andrea has worked on approximately $1 billion of financing and acquisition deals in his career.